Answers are grounded in this paper and cite their sources.
Background: Screening for latent tuberculosis (TB) is mandatory in inflammatory bowel disease (IBD) before starting anti-tumor necrosis factor therapy. Data on the utility of screening tests in populations with moderate background risk of TB are limited. This study aims to evaluate the performance of interferon-gamma release assay (IGRA) with QuantiFERON-TB Gold in IBD patients in a TB endemic region.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: